The Novel 18F-labeled MAO-B PET Tracer Study in Parkinsonism Patients

The Novel 18F-labeled MAO-B PET/CT Imaging on Parkinsonism Patients of Chinese Population: a Prospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06010290

Enrollment

Registered

2023-08-24

Start date

2022-11-30

Completion date

2023-12-31

Last updated

2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

PET/CT

Brief summary

This study mainly aims to prospectively evaluate the changes of reactive astrogliosis in Parkinsonism patients of Chinese population by the novel 18F-labeled MAO-B PET tracer.

Detailed description

18F-SMBT-1, the novel 18F-labeled MAO-B PET tracer, was evaluated reactive astrogliosis in Alzheimer's disease successfully. In this prospective study, we assess the changes of reactive astrocytes in cerebral gray matter and white matter on Parkinson's disease by 18F-SMBT-1 PET/CT imaging among Chinese population.

Interventions

DRUG18F-SMBT-1

Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Aged from 40 to 90 years old. * Clinically diagnosed as Parkinsonism, including Parkinson's disease and atypical Parkinsonism syndromes. * Can cooperate with 18F-FDG PET/CT, 18F-FP-CIT PET/CT and 3D T1-weighted structural MR scans. * Complete clinical data, including modified Hoehn and Yahr staging scale and the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Exclusion criteria

* Cannot cooperate with PET/CT or MR examination. * Associated with brain diseases such as stroke, brain trauma, brain tumor, and cranial surgery.

Design outcomes

Primary

Measure	Time frame	Description
Standard uptake value ratio (SUVR)	60 days	Standard uptake value ratio of 18F-SMBT-1, 18F-FP-CIT and 18F-FDG in the key cerebral regions using the cerebellar cortex or subcortical white matter as a reference region
Clinical parameters	60 days	Clinical parameters include sex, age, Hoehn-Yahr Stage, and Unified Parkinson's disease rating scale (UPDRS).

Secondary

Measure	Time frame	Description
Correlation coefficient 1	60 days	Correlation analysis of SUVR between 18F-SMBT-1, 18F-FP-CIT and 18F-FDG in the key cerebral regions.
Correlation coefficient 2	60 days	Correlation analysis between SUVR of 18F-SMBT-1 PET/CT in the key cerebral regions and clinical parameters.

Countries

China

Contacts

Primary ContactQiang Xie, MD

xieqiang1980@ustc.edu.cn+8613721108043

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026